Object. The literature, at present, provides limited information about extraventricular neurocytomas (EVNs) and is almost exclusively composed of case reports or small case series. Treatment for EVNs has largely been guided by results from central neurocytoma outcome studies. The authors present an analysis of all reported intracranial EVN cases to establish if tumor histopathological features can substratify EVN into groups with differing prognosis and help guide treatment decisions.
xtravEntricular neurocytoma is an exceedingly rare tumor and has only been recently classified as a distinct entity in the WHO 2007 guidelines. 18 As opposed to central neurocytomas, which are located intraventricularly, EVNs are located outside the ventricular system. They are typically intracranial, but a substantial number have been reported outside the cranial vault. 8, 13, 19, 22, 46, 47, 49 They are likely related to central neurocytomas given their associated similar typical histological findings. 7, 33 Because of the rarity of this tumor type and its similarity to central neurocytoma, individual reports have discussed the prognosis and management of EVNs by referring to outcomes observed in central neurocytomas. 25, 42 The literature, at present, provides limited information on EVNs and is almost exclusively composed of case reports and small case series. Furthermore, the authors of a prior review included in their analysis many cases from extracranial locations.
17 Extraventricular neurocytomas located outside the cranial vault are exposed to a different tumor microenvironment, and thus, the study of extracranial EVNs may not help accurately describe and guide treatment for intracranial EVNs that would typically present for neurosurgical care. Because EVNs are not common, their diagnosis is frequently difficult to make and relies heavily on the judicious use of immunohistochemical analysis and electron microscopy. 3, 52 Although EVNs may resemble central neurocytomas, it has been suggested that EVNs are associated with worse prognosis and a more aggressive biological nature. 41 In the present article, we present an analysis of all reported intracranial cases to establish if tumor histopathological features can allow further substratification of EVN into groups with differing prognoses.
Methods

Article Selection
Articles were identified using a PubMed search for "neurocytoma," "neurocytomas," "extraventricular," and "central" alone and in combination. We subsequently searched the references in these articles for further reports. Inclusion criteria included documentation of individual, disaggregated patient data for the following: age, tumor location, histopathological description, treatment description, follow-up duration, and recurrence and mortality data.
Data Extraction
For each article, age, tumor location, treatment modality, histopathological report, follow-up duration, and recurrence and mortality data were extracted for individual patients. Tumor location is summarized in Table 1 . Patients with intraventricular or extracranial tumors were excluded.
Histology Classification
Tumors were classified into either a typical or an atypical category. Atypical tumors were defined by MIB-1 labeling index greater than 3%, or features consistent with higher-grade tumors defined as frequent mitoses, vascular proliferation, or presence of necrosis. 45 
Statistical Analysis
Continuous variables are presented with standard error, and differences across these variables were analyzed using a 2-sided independent-samples t-test. We analyzed differences in categorical variables using the Pearson chisquare test. Kaplan-Meier estimates were used to generate survival curves. Differences in time to recurrence or death from disease were analyzed using the log-rank test. Cox proportional hazard modeling was used to determine HRs and to assess for differences in recurrence and survival, adjusting for differences in preoperative variables. Statistical tests were considered significant when p < 0.05. All descriptive and statistical analyses were performed using SPSS version 16.0 (IBM/SPSS).
Results
Results of the Systematic Review
Our search identified 35 articles Table 2 .
Outcomes for EVNs have a Bimodal Distribution Depending on Histological Subtype
Of the 85 EVNs reported in the literature, 27% were atypical (23 of 85 patients). In 56 patients (66%) atypia was defined by MIB-1 labeling, while in 29 patients (34%) this determination was based on histology. Kaplan-Meier analysis demonstrated significant differences between patients with typical and those with atypical tumors in post-primary treatment 5-year recurrence rate (36% and 68%, respectively; p < 0.001, log-rank test) and 5-year mortality rate (4% and 44%, respectively; p < 0.001, logrank test) (Fig. 1) . The median time to recurrence after initial treatment was 48 months (range 6-216 months) for typical tumors and 21 months (range 5-94 months) for atypical tumors. Only 2 patients in whom histology was typical died during the follow-up course, 1 at 23 months and 1 at 312 months following primary treatment. The median time to death during the follow-up period after initial treatment for patients with atypical tumors was 42 months (range 6-98 months).
Impact of Age on Posttreatment Prognosis of EVNs
Given other reports of a possible association between age and outcomes for patients with EVNs, 3 we assessed the impact of age on prognosis. Analyzing recurrence data by decade of life, we found a sharp increase in recurrence rates in patients in their 6th decade and above (Table 3) . Thus, we performed a Kaplan-Meier analysis on overall recurrence risk for patients ≥ or < 50 years of age. Kaplan-Meier analysis demonstrated significant differences between patients younger than 50 years age and those 50 years of age or older in post-primary treat- ment 5-year recurrence rate (33% and 75%, respectively; p < 0.001, log-rank test) and 5-year mortality rate (4% vs 52%, respectively; p < 0.001, log-rank test).
Given that both histological features of atypia, as well as patient age ≥ 50, appeared, in a univariate analysis, to predict a worse prognosis for patients, we performed a Cox regression analysis for risk of recurrence and death posttreatment. After statistical regression, we found that only histological features of atypia remained a significant predictor of recurrence (HR 4.91, 95% CI 1.96-12.35, p < 0.001) and mortality (HR 22.91, 95% CI 2.82-185.98, p < 0.01). Thus, the significance of older age in univariate analysis is likely related to the high rate of atypical histology found in patients 50 years and older (68% vs 15%, respectively; p < 0.001, chi-square test).
Extent of Resection Predicting Recurrence in Typical EVNs
The extent of resection and adjuvant treatment data were available for 75 patients. Given that tumor histopathology independently affects tumor recurrence, we substratified the extent of resection by atypical or typical histology (Fig. 2) . We found that in cases of typical EVNs, overall recurrence rates were 5% after GTR (1 of 20) and 32% after STR (6 of 19) (p < 0.05, chi-square test). Subtotal resection with adjuvant radiotherapy was associated with a 17% recurrence rate (1 of 6), which was not significantly different than STR alone (chi-square [not significant]). Also of note, in cases of GTR with adjuvant radiotherapy, there were no recurrences of the typical tumors.
Given the overall rarity of EVNs, and particularly atypical EVNs, the population size did not lend itself to statistical analysis for resection extent subgroups. To summarize the published literature on this topic, we found post-primary treatment recurrences for atypical EVNs included 2 of 2 patients receiving STR, 1 of 3 patients receiving GTR, and 4 of 11 patients receiving STR with adjuvant radiotherapy.
Discussion
Because data suggest a worse prognosis in patients with EVNs than in those with central neurocytomas, EVN has been listed as a distinct entity in the new WHO guidelines. 3, 18, 26, 41 However, these observations have been based on individual case reports and case series. Furthermore, due to the rarity of this tumor, worsened outcomes with atypical histology have been inferred from reports on central neurocytoma outcomes, and the existence of a higher tumor grade has not been formally demonstrated for EVNs. 25, 42 We found that atypical histology significantly predicts poor outcomes with higher recurrence and mortality rates. Additionally, we provide some evidence supporting the beneficial effects of a more aggressive surgery.
Analysis of patient outcomes revealed that atypical histology predicted significantly higher rates of recurrence and mortality. Atypical pathology included either MIB-1 labeling index greater than 3%, or atypical histological features of frequent mitoses, vascular proliferation, and necrosis. We found that atypical tumors occurred in 27% of EVN cases and had 2 to 3 times the recurrence risk of typical EVNs, as well as recurring at a much earlier time posttreatment. Likewise, patients harboring tumors with atypical histology had a 10-fold increased risk of death during a follow-up period of 98 months.
Rades and colleagues 35 have reported a 25% rate of atypical histology in central neurocytoma. Atypia and high MIB-1 labeling index have been demonstrated to be significant risk factors in central neurocytomas as well. 37 Recurrence and mortality rates for typical central neurocytomas are not dissimilar from those we found for typical EVNs: 28% recurrence and 5% mortality in typical central neurocytoma compared with 36% recurrence and 4% mortality in typical EVNs. 34 Atypical features appear to lead to higher rates of recurrence and mortality in both central neurocytomas and EVNs: 40% recurrence and 20% mortality in atypical central neurocytoma compared with 68% recurrence and 44% mortality, respectively, in atypical EVNs. 35 The similar histology and clinical behavior of both central and extraventricular neurocytomas may argue against the idea that the EVN is actually a distinct disease from central neurocytoma. Although the higher rates of recurrence and mortality observed in atypical EVNs, compared with atypical central neurocytomas, could be explained by differing tumor biology, we believe that this likely reflects the relationship between the anatomical localization of tumor growth and symptom appearance. Atypical central neurocytomas may cause symptoms of hydrocephalus that lead to presentation at a much earlier stage by obstructing the narrow outflow tracts of the ventricular system. Cortical based EVNs may not cause symptoms until they are much larger in size and may be in closer proximity to critical neurovascular structures. These differences could potentially lead to earlier intervention and a higher chance of GTR without complications in atypical central neurocytoma. In fact, GTR was achieved in 33% of atypical central neurocytomas 35 compared with 13% of atypical EVNs.
Prior reports have suggested that age may be a risk factor for poor prognosis in EVNs. 3 Analysis of the published literature demonstrated age over 50 years is a risk factor in isolation. However, when rates of higher-grade tumors are controlled for using regression analysis, age does not appear to be an independent risk factor. Regardless, given the associations of atypia and age with poor outcomes, these data suggest that atypical histology and older age may be in the same epidemiological pathway in tumor progression for EVNs.
The extent of resection and adjuvant treatment is commonly correlated with patient outcomes in a variety of tumor types. In patients with central neurocytoma, GTR or STR with adjuvant radiotherapy results in superior rates of tumor control than STR. 33, 34, 36 Our analysis demonstrates that GTR of EVNs results in significantly lower recurrence rates than STR alone in typical tumors, and there is a suggestion that adjuvant radiotherapy may improve recurrence rates following STR. Based on the limited available data, both GTR and STR with adjuvant radiotherapy appear to offer better posttreatment tumor control rates for atypical EVNs. It is important to note that GTR is often difficult to achieve in cases of atypical EVNs, and in our review we found only 13% of atypical tumors received GTR.
Although our results are informative, there are limitations to our analysis. Given the relatively modest total number of cases reported, and the nature of our disaggregated analysis, we were not able to use formal metaanalytical methods to limit the impact of between-center heterogeneity. Of note, however, individual centers typically do not have enough cases to determine a quantitative measurement of heterogeneity that would be needed in a meta-analysis. The statistical methods in this paper use the individual patient data approach to combine disaggregated data to achieve survival estimates. This method has been validated compared with other fixed-effects models, and the Cochrane Collaboration considers it the optimal approach for survival analysis. 9 Our results are, however, a summary of the literature and reliant on the quality of the composite studies and could therefore suffer from selection bias and source study bias. Furthermore, given the heterogeneity of treatment and relatively modest total patient number, we could not control for the extent of resection and adjuvant treatment effects in a multivariate analysis. Additionally, we were not able to control for individual differences in data analysis and presentation across the different studies included in our analysis. Thus, this study is not the ideal form of meta-analysis and does not, and cannot, conform to formal standards of metaanalysis. While review of Class III data is less than ideal, in the case of these tumors, it probably represents the best available attempt to consolidate information on a uncommon lesion because Class I data probably will never be available; yet clinicians still need to treat these patients. This effort represents the best effort to work within this context to provide some guidance on the prognosis and management of these rare lesions.
Conclusions
We provide data supporting the existence of at least 2 distinct histological subtypes of EVN, with different prognostic significances. Notably, these findings confirm that atpyia is a significant predictor of poor prognosis specifically for EVNs. Furthermore, complete resections or more aggressive attempts at providing adjuvant therapy following STR appear to improve the prognosis for patients with typical and perhaps atypical EVNs. Given the high mortality rate of atypical EVNs even with adjuvant radiotherapy, future studies should focus on determining successful chemotherapy regimens and identifying novel molecular markers for targeted adjuvant therapies. 
